Alpha 2.0
Login Register
» Authors » M Michallet

M Michallet

Explore the profile of M Michallet including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 191
Citations 2519
Followers 0
Related Specialties
General Surgery
Hematology
Oncology
Top 10 Co-Authors
D Blaise
J Reiffers
N Milpied
D Maraninchi
M Attal
X Thomas
M Mohty
G Socie
J P Jouet
I Yakoub-Agha
Published In
Bone Marrow Transplant
Leukemia
Br J Haematol
Blood
J Clin Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Chronic disseminated candidiasis and acute leukemia: Impact on survival and hematopoietic stem cell transplantation agenda
Grateau A, Le Marechal M, Labussiere-Wallet H, Ducastelle-Lepretre S, Nicolini F, Thomas X, et al.
Med Mal Infect . 2018 Jan; 48(3):202-206. PMID: 29307444
Objectives: To study the management of chronic disseminated candidiasis (CDC) in patients presenting with acute leukemia. Patients And Methods: Single-center retrospective study of acute leukemia patients (2006-2015) to investigate three...
2.
Outcome of Frontline Treatment with "Generic" Imatinib In Adult Patients with Chronic Myeloid Leukemia in Algerian Population: A Multicenter Study
Entasoltan B, Bekadja M, Touhami H, Mehalhal N, Zouaoui Z, Mesli N, et al.
Mediterr J Hematol Infect Dis . 2017 Nov; 9(1):e2017062. PMID: 29181139
Introduction: In a developing country like Algeria, such expensive therapy is not available. Alternative approaches are needed to help these adult. In Algeria 'imatib' (CIPLA-India) was introduced in 2006; but...
3.
Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT
Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Sanz J, et al.
J Intern Med . 2017 Oct; 283(2):178-189. PMID: 28977716
Background: The efficacy of umbilical cord blood transplantation (UCBT) as treatment for acute myeloid leukaemia (AML) relies on immune-mediated graft-versus-leukaemia effects. Previous studies have suggested a strong association between graft-versus-host...
4.
How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome
Yafour N, Beckerich F, Bulabois C, Chevallier P, Daguindau E, Dumesnil C, et al.
Curr Res Transl Med . 2017 Jul; 65(2):65-69. PMID: 28687223
Disease relapse remains the first cause of mortality of hematological malignancies after allogeneic hematopoietic stem cell transplantation (allo-HCT). The risk of recurrence is elevated in acute myeloid leukemia (AML) patients...
5.
Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
Michallet M, Chapuis-Cellier C, Dejoie T, Lombard C, Caillon H, Sobh M, et al.
Leukemia . 2017 Jul; 32(2):376-382. PMID: 28663581
Novel anti-myeloma agents have improved patient response rates, which are historically based on reductions of the M-protein. These methods can be inaccurate for quantifying M-proteins at low concentrations. We compared...
6.
Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de...
Nguyen S, Achour A, Souchet L, Vigouroux S, Chevallier P, Furst S, et al.
Bone Marrow Transplant . 2017 Jun; 52(10):1428-1435. PMID: 28650455
Unrelated cord blood transplantation (UCBT) after a reduced intensity conditioning regimen (RIC) has extended the use of UCB in elderly patients and those with co-morbidities without an HLA-identical donor, although...
7.
Skin allograft for severe chronic GvHD
Crocchiolo R, Dubois V, Nicolini F, Sobh M, Ducastelle-Lepretre S, Labussiere H, et al.
Bone Marrow Transplant . 2017 Mar; 52(7):1060-1062. PMID: 28346413
No abstract available.
8.
Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation
Schetelig J, de Wreede L, van Gelder M, Andersen N, Moreno C, Vitek A, et al.
Bone Marrow Transplant . 2017 Jan; 52(4):552-560. PMID: 28112746
For young patients with high-risk CLL, BTK-/PI3K-inhibitors or allogeneic stem cell transplantation (alloHCT) are considered. Patients with a low risk of non-relapse mortality (NRM) but a high risk of failure...
9.
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT
Battipaglia G, Labopin M, Candoni A, Fanin R, El Cheikh J, Blaise D, et al.
Bone Marrow Transplant . 2017 Jan; 52(4):592-599. PMID: 28092357
Gemtuzumab ozogamicin (GO) may increase the risk of sinusoidal obstruction syndrome (SOS) when used prior to allogeneic stem cell transplantation (HSCT). We assessed SOS incidence and outcomes after HSCT of...
10.
Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy
Gauthier J, Castagna L, Garnier F, Guillaume T, Socie G, Maury S, et al.
Bone Marrow Transplant . 2017 Jan; 52(5):689-696. PMID: 28067872
Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor...